ANZCTR search results

We aim to determine if a 6-session course of reconsolidation blockade (i.e., oral propranolol treatment combined with script-driven trauma recall) is efficacious in reducing PTSD symptom frequency and severity in adults 18years +. We will also examine the psychosocial, neurocognitive, neurobiological, neuroimaging and physiological effects of reconsolidation blockade treatment in adult participants with PTSD. Our research questions include: 1. Primary question: Will a 6-session reconsolidation blockade treatment be efficacious in reducing core PTSD symptoms frequency and severity? 2. Secondary question: Are there psycho-social, cognitive, and biological markers (genetic, circulating, and neural) that can predict treatment response to reconsolidation blockade treatment?

This is a study to determine if the FUNCAP 27 can be used as an instantaneous measure of perceived functional capacity in those with ME/CFS and Long Covid when at baseline and in a state of PEM(Post Exertional Malaise). We are doing this to establish a measure that can detect short term fluctuations in health that will be used in later interventional clinical trials. We aim to recruit 1000 participants for 2 questionnaires and 1 enrolment survey taking 6-20 minutes at enrolment (including reading the consent forms), 15-35 minutes when well and 10 -20 minutes in PEM. The questionnaire can be completed with the aid of a carer and paused for completion at a later time.

In the intensive care unit (ICU), non-invasive ventilation (NIV) is a treatment option for patients with respiratory failure. NIV involves the delivery of oxygenated air from a ventilator to the patient via a mask. The mask is secured to the patient’s head using straps that sit around the head to hold the mask over the nose and mouth. The purpose of NIV is to reduce the likelihood of invasive mechanical ventilation that requires the insertion of an artificial airway or breathing tube. Traditionally NIV masks cover the entire nose and mouth, resting on the nasal bridge. This can in rare instances lead to the development of pressure injuries on the bridge of the nose and as such facial disfiguration. At Sunshine hospital the Nivairo® mask is routinely used for NIV. This mask sits across the nasal bridge. In this study we would like to determine if the Visairo® mask that does not have a nasal bridge is equivalent to the Nivairo® mask for the delivery of NIV.

This study aims to assess the safety and feasibility of using tranexamic acid (TXA) in patients with cerebral amyloid angiopathy (CAA) and symptomatic brain bleeding to determine if TXA can reduce risk of recurrent intracranial haemorrhage without harmful side effects. We hypothesise TXA to be a safe and well tolerated treatment option for patients with CAA in reducing their risk of recurrent brain bleeding. Participants will be recruited from Alfred Health and Royal Melbourne Hospital, diagnosed with probable CAA, who have had previous brain bleeding within the last 6 months. They will be randomly assigned to take either 1 gram of TXA orally three times per day or an identical placebo for 6 months. All participants will have MRI scans with contrast and blood tests at the start and end of the study to measure biomarkers. Researchers will track participants' compliance with the treatment and any adverse events over the 6-month period. Primary outcomes will include feasibility measures (participation and adherence rates) and safety (monitoring for serious adverse events like clotting conditions, heart attacks, strokes, or death). Secondary outcomes will track the recurrence of various brain haemorrhages, progression of white matter changes, changes in cognitive function, and brain volume loss, as well as the development of new strokes.

This study is a data collection study of the EMVision emu™ brain scanner for patients not suffering from or suspected of suffering from an acute stroke for software algorithm development. This study collects EMVision brain scans and MRI scans from patients receiving a head MRI as part of their routine care. Scans are anonymised and enter the EMVision database for training and developing software algorithms. This study hypothesises that an expanded non-stroke dataset can improve the diagnostic performance of the emu™ brain scanner.

The aim of this study is to test whether MDMA-assisted psychotherapy reduces social anxiety in young autistic people, compared with medication-assisted psychotherapy using: • Dexamfetamine • Lorazepam • Diphenhydramine hydrochloride, and • placebo. We hypothesise that MDMA-assisted psychotherapy will reduce social anxiety more than medication psychotherapy with placebo or the active control medications. Young people with autism, aged 16 to 25 years and experiencing social anxiety can take part in this research. The study will involve assessment for autism if participants have not been diagnosed in the past year. Participation will involve taking part in a medication-assisted psychotherapy program over a period of 12 weeks in addition to participating in a number of research assessments for approximately one year.

Most people diagnosed with dementia will experience at least one type of behavioural and psychosocial symptoms of dementia (BPSD), however the prevalence varies across the literature, with up to 95% of people living with dementia experiencing BPSD during their hospital admission. BPSD may also result in inappropriate psychotropic prescribing, falls, distress, and death. Over the past decade, virtual reality (VR) technologies have gained interest as a novel therapeutic intervention for dementia. VR therapy provides a potential non-pharmacological approach to managing BPSD and minimising distress during an acute hospital admission. To date, no randomised control trial has been done on the use of VR therapy in the acute hospital setting in Australia.

Rehabilitation is crucial for recovering motor functions after injuries like spinal cord injury (SCI) or stroke. Traditional methods often require a lot of manual effort from therapists, making them time-consuming and less effective for patients with limited or no motor control. Brain-computer interfaces (BCIs) offer a promising alternative by converting brain signals into commands that assist devices, enabling automated therapy without constant manual input. Our study focuses on training individuals, especially those new to BCIs, to use their imagination to control these systems in a virtual reality (VR) environment. This approach could make rehabilitation more efficient, engaging, and accessible for people with severe motor impairments.

The aim of this study is to deliver a new evidence-based education program in hospitals called the Safe Recovery program and to evaluate if it reduces falls and injuries. The study will also measure changes in patient and staff knowledge and motivation about falls prevention and if they are taking actions to reduce falls. Falls education is known to reduce patient falls and injuries in hospital. If effective the program will reduce falls and injuries in the wards that take part in the trial.

PURPOSE The purpose of this study is to assess the feasibility of patient self-administration of daratumumab in patient's own home. WHO IS IT FOR? You may be eligible for this study if you are male or female aged 18 years or older, have a documented diagnosis of multiple myeloma. Have relapsed following first line therapy and require treatment with daratumumab, bortezomib and dexamethasone. STUDY DETAILS Daratumumab, bortezomib and dexamethasone is standard of care. Daratumumab is currently administered in the hospital. Bortezomib can be administered home if your hospital has programs in place for this to happen. Dexamethasone is a tablet that you can take in your own home. The Dara@home trial is to assess the feasibility of implementing a program to allow patients to self-administer daratumumab at home. In addition to standard tests used to treat and monitor your myeloma, this study will have additional questionnaires for you to report your experience with myeloma treatment. There is also an additional blood test to assess the level daratumumab in your blood to ensure that the treatment is working. It is hoped that findings from this study will give insight on the possibility of having daratumumab to be self-administered at home, which can reduce your visits to the hospital.